VINCERX PHARMA INC (VINC) Stock Price, Quote, News and Summary
NASDAQ:VINC - Nasdaq - US92731L1061 - Common Stock
VINC Quote and Key Statistics
VINCERX PHARMA INC
NASDAQ:VINC (1/17/2025, 8:00:01 PM)
After market: 0.152 0 (-0.2%)0.1523
+0.01 (+8.71%)
VINC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.84% | ||
| ROE | -296.77% | ||
| Debt/Equity | 0 |
VINC Performance and Technical Analysis
VINC Ownership and Analysts
VINC Latest News and Analysis
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Curious about the stocks that are showing activity after the closing bell on Thursday?
Curious about the stocks that are showing activity after the closing bell on Thursday?
Thursday's after hours session: top gainers and losers
Unusual volume stocks in Tuesday's session
Which stocks have an unusual volume on Tuesday?
Curious about the stocks that are showing activity after the closing bell on Monday?
Curious about the stocks that are showing activity after the closing bell on Monday?
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders
About VINC
Company Profile
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 42 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. The company consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Company Info
VINCERX PHARMA INC
260 Sheridan Avenue, Suite 400
Palo Alto CALIFORNIA 94306 US
CEO: Ahmed M. Hamdy
Employees: 42
Company Website: https://vincerx.com/
Investor Relations: https://investors.vincerx.com/
Phone: 16508006676
VINC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |